Drug Trial Radar · NCT07463040
Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)
Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
Jan 1, 2027
Primary completion
Mar 1, 2029
Study completion Aug 31, 2029
Sponsor
- Lead sponsor
- Institute of Tropical Medicine, BelgiumAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- London School of Hygiene and Tropical Medicine; Uppsala University; University of Stellenbosch; Armauer Hansen Research Institute, Ethiopia; Wollo University; Arba Minch University
- First posted
- Mar 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 4 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MAMS4CL comprises a clinical trial with three embedded sub-studies designed to comprehensively evaluate the administered treatments and assess the impact of CL treatment on patients and the healthcare system. The multi-centre multi-arm multi-stage phase 3 clinical trial is designed to rigorously evaluate a total of 4 alternative treatment options for systemic CL against Sodium Stibugluconate (SSG) as the standard of care. The trial comprises two seamlessly linked stages. In stage 1, all four investigational arms will be evaluated against the control arm for efficacy to inform the selection of the arms, based on a pre-defined efficacy threshold that will advance to stage 2, in addition to the control arm. After stage 2, the experimental interventions will be compared with SSG similar to a standard superiority trial for efficacy. The general study design in stage 1 and stage 2 will be identical; only the number of investigational arms may differ. Patients will be randomized into the respective treatment arms at the recruitment sites of Arba Minch hospital, Boru Meda hospital and ALERT hospital in Ethiopia. Individuals will be hospitalized during the entire course of their treatment. As different arms have different treatment duration, patient hospitalization period and visit schedules will differ between arms. In total, the study will last 180 days for each participant.
Conditions
- Cutaneous Leihmaniasis
Interventions
Sodium Stibogluconate (SSG)Drug
Intramuscular Administration - once daily for 28 days
MiltefosineDrug
Miltefosine - Oral Administration, daily for 28 days
Miltefosine + ParomomycinDrug
Miltefosine - Oral Administration, daily for 28 days + Paromomycine - Intramuscular Administration, once daily for 14 days
Liposomal Amphotericin B (LAmB)Drug
Intravenous Administration, once daily on days 1, 3, 5, 7, 10, 12, 14, 17, 19, 21
Pentamidine isethionateDrug
Intravenous Administration - once daily on days 1, 3, 5, 7, 9, 11, 13
Primary outcomes
What the sponsor says the trial is designed to measure.
- For each of the investigational arms (miltefosine/miltefosine + paromomycin / liposomal amphotericin B/pentamidine isethionate), to determine whether it has superior efficacy to the control arm in terms of achieving cure of all lesions at Day 90Time frame: Day 90
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
ALERT Hospital
Addis Ababa, Ethiopia
Arba Minch General Hospital
Arba Minch, Ethiopia
Boru Meda General Hospital
Boru, Ethiopia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.